Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

Title: Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

Volume: 3 Issue: 4

Author(s): Seiji Ueda, Sho-ichi Yamagishi, Yuriko Matsumoto and Seiya Okuda

Affiliation:

Keywords: ADMA, CKD, cardiovascular risk, dimethylarginine, dimethylarginine dimethylaminohydrolase, oxidative stress, NO

Abstract: Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step in the course of atherosclerotic cardiovascular disease. NO is synthesized from L-arginine via the action of NO synthase, which is known to be blocked by endogenous L-arginine analogues such as asymmetric dimethylarginine (ADMA). ADMA is a naturally occurring amino acid found in plasma and various types of tissues. Plasma level of ADMA is reported to be associated with cardiovascular risk factors such as chronic kidney disease (CKD), being a strong predictor for cardiovascular disease and the progression of renal dysfunction in these patients. In this review, we discuss the molecular mechanisms for the elevation of ADMA levels in CKD. We also review here the pathological role for ADMA in cardiovascular complications in patients with CKD.

Cite this article as:

Ueda Seiji, Yamagishi Sho-ichi, Matsumoto Yuriko and Okuda Seiya, Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease, Current Enzyme Inhibition 2007; 3 (4) . https://dx.doi.org/10.2174/157340807782330200